IL-1-IL-17 Signaling Axis Contributes to Fibrosis and Inflammation in Two Different Murine Models of Systemic Sclerosis

Min-Jung Park1†, Su-Jin Moon2†, Eun-Jung Lee1, Kyung-Ah Jung1, Eun-Kyung Kim1, Da-Som Kim1, Jung-Ho Lee3, Seung-Ki Kwok2, Jun-Ki Min2, Sung-Hwan Park2*† and Mi-La Cho1*†

1 The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, South Korea, 2 Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea, Seoul, South Korea, 3 Department of Plastic and Reconstructive Surgery, College of Medicine, The Catholic University of Korea, Seoul, South Korea

Objective: Systemic sclerosis (SSc) is a progressive fibrotic disease that affects the skin and internal organs. Despite evidence implicating increased interleukin-17 (IL-17) activity in SSc, the role of IL-17 in SSc remains uncertain. The purpose of this study was to investigate whether IL-17 plays a pathophysiological role in SSc in two different murine models of SSc.

Methods: Bleomycin (BLM)-induced fibrosis and chronic graft-versus-host disease (cGVHD) models were used. Histological analysis was performed using Masson's trichrome and immunohistochemical staining. Quantitative reverse transcription-polymerase chain reaction and enzyme-linked immunoassays were used to quantify the messenger RNA and protein levels of inflammatory mediators in dermal fibroblasts.

Results: IL-1 receptor antagonist-deficient (IL-1Ra-KO) mice were more severely affected by BLM injection, as shown by dermal and pulmonary fibrosis, compared with wild-type (WT) mice. Increased tissue fibrosis was reversed by knocking down IL-17. In vitro experiments showed that IL-1 and IL-17 exerted synergistic effects on the expression of profibrotic and inflammatory mediators. In the cGVHD model, C57BL/6 mice receiving splenocytes of IL-1Ra-KO BALB/c mice developed more severe cGVHD than did those receiving cells from WT mice. Knockdown of IL-17 in IL-1Ra-KO donor mice significantly attenuated the IL-1-induced acceleration of cGVHD severity.

Conclusion: Targeting IL-1 and its downstream IL-17 activity may be a novel treatment strategy for inhibiting inflammation and tissue fibrosis in SSc.

Keywords: systemic sclerosis, skin fibrosis, lung fibrosis, interleukin-17, interleukin-1, chronic graft-versus-host disease

INTRODUCTION

Systemic sclerosis (SSc) is a progressive fibrotic disease that is characterized by excessive deposition of extracellular matrix (ECM) components such as collagen and glycoprotein (1). The clinical manifestation and course of SSc are highly heterogeneous. Although the pathogenesis of the disease is complex and remains unknown, vascular damage and inflammation associated with activated innate and adaptive immunity are considered to be involved in the pathological mechanisms underlying the
tissue fibrosis, particularly in the skin and visceral organs such as the lung and gastrointestinal tract. Lung fibrosis is a common clinical manifestation of SSc and is the leading cause of death in affected patients.

Injury-induced activation of vascular endothelial cells is the initial and central event of SSc. Activated vascular endothelial cells can induce the perivascular infiltration of inflammatory cells such as CD4+ T cells, which can produce high levels of inflammatory cytokines such as interleukin 4 (IL-4) (2, 3). CD4+ T cells have recently been shown to be centrally involved in the pathogenesis of SSc. In addition to vasculopathy and fibrosis, activated autoimmunity is another hallmark of SSc. In the preclinical or very early phase, the pathological changes in skin affected by SSc include perivascular edema and inflammatory cell infiltration (4). Increased dermal fibrosis, decreased number of normal capillaries, and loss of skin adnexa are the typical pathological findings that appear in the established stage of SSc (4). In lungs affected by SSc, inflammatory cell infiltration in the interstitium and alveoli precedes evident pulmonary fibrosis (5). These observations strongly suggest that the infiltration of inflammatory cells such as CD4+ T cells is the first event in the process leading to the generalized tissue fibrosis in SSc.

Th17 cells are a CD4+ T cell subset that secrete primarily IL-17 (IL-17A and IL-17F). Th17 cells and the associated signaling pathways have been shown to be involved in the pathogenesis of many autoimmune and inflammatory diseases, such as rheumatoid arthritis, Sjögren’s syndrome, and type 1 diabetes (6). It has been suggested that the production of IL-17 is increased in SSc patients (7, 8). IL-17 directly promotes the production of IL-6 and IL-8 in human dermal fibroblasts (9). In vitro studies have shown that IL-17 increases the proliferation of fibroblasts and IL-1 production in vascular endothelial cells, which suggests a pivotal role of IL-17 in fibrosis and endothelial inflammation (7, 10). Interestingly, many inflammatory cytokines, such as TGF-β, IL-6, and IL-1, which are known to be involved in the pathogenesis of SSc, are mediators that promote Th17 differentiation. This strongly suggests the skewing of CD4+ T cell immune response toward Th17 in the disease. However, existing evidences shown in human and experimental animal models of SSc have failed to reach a definite conclusion (11–13). Skin biopsy samples obtained from SSc patients showed the increased population of IL-17+ cells compared to those of healthy controls, and IL-17 attenuated the myofibroblast transdifferentiation, suggesting its antifibrotic role during dermal fibrosis in SSc (11). On the other hand, another study showed the close relationship between SSc disease activity and the number of Th17 cells (14). They also identified that IL-17 derived from Th17 cells promoted collagen production and fibroblast growth (14).

Here, we used two different murine models to examine whether IL-17 activity could augment the fibrotic and inflammatory processes in SSc. In vivo studies showed that IL-17 signaling is critically involved in the fibrosis and inflammation processes in a bleomycin (BLM)-induced model of SSc. We also used a chronic graft-versus-host disease (cGVHD) model, another murine model of SSc, to show that blocking IL-17 activity attenuated the clinical severity of cGVHD. IL-1 and IL-17 had synergistic effects on the expression of profibrotic and inflammatory mediators in dermal fibroblasts from humans and mice. We confirmed the antifibrotic and anti-inflammatory potentials of IL-1 receptor antagonist (IL-1Ra) in vivo. These findings suggest that an IL-17 cytokine-targeting strategy by blocking IL-1 may be a novel therapeutic strategy to inhibit generalized tissue fibrosis in SSc patients.

MATERIALS AND METHODS

Mice

B6 (H-2kb) and B/c (H-2kd) female mice, 8–10 weeks of age, were purchased from OrientBio (Gungnam, Korea). IL-1Ra knockout (KO) and IL-17 KO mice were obtained from Prof. Voichiro Iwakura (University of Tokyo, Japan). IL-1Ra-KO mice were backcrossed to IL-17 KO mice over 10 generations, and double KO (DKO) mice were selected for use in polymerase chain reaction (PCR) analysis. The mice were given standard mouse chow (Ralston Purina Co., St. Louis, MO, USA) and water ad libitum. All experimental procedures were examined and approved by the Animal Research Ethics Committee of the Catholic University of Korea (Seoul, Korea).

BLM Treatment

Female mice (aged 6–8 weeks) were anesthetized with isoflurane, and their backs were shaved. Mice were treated daily for 4 weeks with subcutaneous injections of phosphate-buffered saline (PBS) or BLM (Dong-A Pharm, Seoul, Korea). BLM was given at a dose of 1 mg/ml in PBS and was sterilized by filtration before injection into the shaved back skin. The mice (n = 5 or 6 per group) were killed by CO2 euthanasia on the day after the final treatment, and the back skin and lungs were harvested and fixed in 10% formalin solution for histological analysis.

Bone Marrow (BM) Transplantation

C57BL/6 recipient mice were intravenously injected with 5 × 10⁶ donor BM cells after lethal irradiation with 800 cGy. Splenocytes (1 × 10⁶ cells) from wild-type (WT) BALB/c or IL-1Ra-KO or IL-1Ra–IL-17-DKO mice were injected intravenously through the tail vein. Mice were monitored for body weight after BM transplantation (BMT) at least twice weekly. Mice were euthanized on day 60 after BMT, and the histopathology of their cGVHD target tissues (skin, lung, liver, and large intestines) was analyzed by investigators who were blinded to the treatment. Organs were harvested, cryoembedded, and sectioned. The sections were fixed in 10% (v/v) buffered formalin and stained with H&E for histological examination.

Histopathological Assessment

Tissues were fixed in 10% formalin and embedded in paraffin. Sections (6 µm thick) were stained with H&E and Masson's trichrome (MT). Dermal thickness was examined as previously described (15). The lungs were excised, and the severity of fibrosis was scored as previously described (16). To quantify the amount of collagen in mouse skin and lung tissues, skin and lung was hydrolyzed and used for hydroxyproline assay. Immunohistochemistry was performed using VECTASTAIN ABC kits (Vector Laboratories, Burlingame, CA, USA). Tissues
were first incubated with the primary antibodies to IL-1β, IL-6, IL-17, tumor necrosis factor α (TNF-α), transforming growth factor β (TGF-β), and α-smooth muscle actin (α-SMA) overnight at 4°C. The primary antibody was detected with a biotinylated secondary linking antibody, followed by incubation with a streptavidin–peroxidase complex for 1 h. The final color product was developed using DAB chromogen (Dako, Carpenteria, CA, USA). The count of positive cells, identified as a dark-brown deposit in nuclei of lymphocytes, was made in 10 randomly selected high power fields (HPF, 400×; 2.37 mm²). To quantify the numbers of infiltrating T cells, B cells, and macrophages, lesional skin sections were stained for CD3, CD22, and F4/80 (Abcam, Cambridge, UK), respectively. The count of positive cells, identified as a discrete membrane staining in cells, was made in 10 randomly selected HPF (400×; 2.37 mm²).

**Collagen Assay**
To quantify the amount of collagen in mouse skin and lung specimens, hydroxyproline content was measured using a commercial Quickzyme Total Collagen Assay kit (QuickZyme Biosciences). The hydroxyproline assays were performed according to the manufacturer's protocol.

**Cell Sources and Culture**
Mouse skin fibroblasts were isolated by enzymatic digestion of skin from normal BALB/c, as described previously (17). Human dermal fibroblasts were isolated from foreskin tissue obtained from healthy humans and WT BALB/c mice performed in accordance with the Helsinki II Declaration. Dermal fibroblasts were isolated from IL-1Ra-KO mice (postnatal days 0–4 mice) and from IL-1Ra-KO mice (tissue 4°C). The primary antibody was detected with a biotinylated secondary linking antibody, followed by incubation with a streptavidin–peroxidase complex for 1 h. The final color product was developed using DAB chromogen (Dako, Carpenteria, CA, USA). The count of positive cells, identified as a dark-brown deposit in nuclei of lymphocytes, was made in 10 randomly selected high power fields (HPF, 400×; 2.37 mm²). To quantify the numbers of infiltrating T cells, B cells, and macrophages, lesional skin sections were stained for CD3, CD22, and F4/80 (Abcam, Cambridge, UK), respectively. The count of positive cells, identified as a discrete membrane staining in cells, was made in 10 randomly selected HPF (400×; 2.37 mm²).

**Th17 Differentiation of Murine T Cells**
Spleens that were isolated from IL-1Ra-KO mice were minced and the red blood cells were lysed with 0.83% ammonium chloride. The cells were filtered through a cell strainer and centrifuged at 1,300 revolutions per minute at 4°C for 5 min. To purify splenic CD4⁺ T cells, the splenocytes were incubated with CD4-coated magnetic beads and isolated using magnetic-activated cell sorting separation columns (Miltenyi Biotec). Positively selected splenic CD4⁺ T cells were stimulated with plate-bound anti-CD3 (0.5 µg/ml), soluble anti-CD28 (1 µg/ml; both from BD Biosciences), anti-interferon-γ (2 µg/ml), anti-IL-4 (2 µg/ml), recombinant transforming growth factor β (2 ng/ml), and recombinant IL-6 (20 ng/ml) (all from R&D Systems) for 3 days to achieve polarization of Th17 cells.

**Real-Time PCR**
Messenger RNA (mRNA) was extracted using TRI Reagent (Molecular Research Center, Inc., Cincinnati, OH, USA) according to the manufacturer's instructions. Complementary DNA was synthesized using a SuperScript Reverse Transcription system (Takara Bio Inc., Kyoto, Japan). A Light-Cycler 2.0 instrument (software version 4.0; Roche Diagnostics, Mannheim, Germany) was used for PCR amplification. All reactions were performed using the LightCycler FastStart DNA Master SYBR Green I mix (Takara), following the manufacturer's instructions. The following primers were used to amplify mouse genes: for IL-1β, 5'-TGG GCA GAT CAT GAC ATT C-3' (sense) and 5'-GGA AGA CAT GAG CAC ACT-3' (antisense); for TGF-β, 5'-GCA GAC ACC TGG CCC TCC C-3' (antisense) and 5'-GAG CAC TCG CCC TCC C-3' (sense) for IL-6, 5'-AGA CAG CTT GTC ACT CGA ATT C-3' (sense) and 5'-TAC AGG CTT GTC ACT CGA ATT C-3' (antisense); for MMP-9, 5'-TCA AGT TTA ACT GGA A-3' (sense) and 5'-GGC TGC CAG TGC CTC TTT GCT G-3' (antisense); for MMP-1, 5'-AAC TAC ATT TAG GGG AGA GGT GT-3' (sense) and 5'-AGA CAG TCA AGT TTA ACT GGA A-3' (antisense); for MMP-9, 5'-TCT TAA TCC AGC ACA GC-3' (antisense) and 5'-AGG CTC TGT TGG GCC CCA-3' (sense) for MMP-1, 5'-AGA CAG TCA AGT TTA ACT GGA A-3' (antisense); for TGF-β, 5'-GGC TGA GTG GTC TTT TAC GCA-3' (sense) and 5'-CAG GGT GCA TCG CCC TCC C-3' (antisense); and for TGF-β, 5'-AGA CAG CTT GTC ACT CGA ATT C-3' (sense) and 5'-CAG GGT GCA TCG CCC TCC C-3' (antisense). All mRNA levels were normalized to that of β-actin.

**Enzyme-Linked Immunosorbent Assay (ELISA)**
The concentrations of IL-1β, IL-1Ra, IL-6, IL-17, and TGF-β in culture supernatants were measured using a sandwich ELISA (DuoSet; R&D Systems, Lille, France). To activate
latent TGF-β1 to the immunoreactive form, before being assayed, latent TGF-β1 was activated to the immunoreactive form by acid treatment. Briefly, 125 µl of cell culture supernatant was incubated with 25 µl of 1 N HCl for 10 min at room temperature, neutralized by addition of 25 µl of 1.2 N NaOH/0.5 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid for 10 min. Serum concentrations of IgG antibodies were measured using a commercial ELISA kit (Bethyl Laboratories, Montgomery, TX, USA).

Statistical Analysis
Data are presented as mean ± SDs of at least three independent experiments or at least three independent samples and for 10 mice in each group. In vitro experiments were independently repeated three or more times and each experiment had at least three samples. One-way analysis of variance followed by Bonferroni’s post hoc test was used to compare differences between ≥3 groups. The Mann–Whitney U test was used to compare numerical data between two groups. To assess the Gaussian distribution and the equality of variance, Shapiro–Wilk test and Levene test were used, respectively. p < 0.05 was considered statistically significant. Statistical analysis was performed using IBM SPSS Statistics 20 for Windows (IBM Corp., Armonk, New York, NY, USA).

RESULTS
Effects of IL-1β and IL-17 on Gene Expression of IL-6, MMP-9, Col1A1, and TGF-β
Many studies have revealed mediators involved in the fibrosis of SSc. IL-6 has been suggested as a treatment target for SSc. IL-6 induces collagen production in skin fibroblasts through JAK2–STAT3-dependent signaling (19, 20). The serum IL-6 level is significantly higher in SSc patients than in healthy people (21), and the level correlates with skin thickness in SSc patients (22). In addition to IL-6, matrix metalloproteinase (MMP), type 1 collagen, and excessive TGF-β activity are revealed to be closely associated with pathological fibrosis in SSc patients (23). MMP-9 is thought to be implicated in fibrotic diseases, such as pulmonary fibrosis (24), and skin fibrosis in SSc patients (25). To study whether IL-1β and IL-17 have a direct effect on IL-6, MMP9, type 1 collagen, and TGF-β expression, we assessed the expression of profibrotic markers in mouse and human skin fibroblasts. In mouse skin fibroblasts, the mRNA expression levels of IL-6 and MMP-9 were increased by IL-1β or IL-17 treatment. In addition, IL-1β and IL-17 showed synergistic effects on IL-6 and MMP-9 mRNA expression in mouse dermal fibroblasts (Figure 1A). By contrast, the expression levels of Col1A1 and TGF-β mRNA were not affected by IL-1β and IL-17.

Next, we examined the effects of IL-1β and IL-17 on the markers mentioned in human dermal fibroblasts. Although each cytokine increased the mRNA expression of IL-6, MMP-9, Col1A1, and TGF-β, the changes were marginal. IL-1β and IL-17 showed significant synergistic effects on IL-6, MMP-9, Col1A1, and TGF-β expression (Figure 1B). To confirm the changes in the protein levels of IL-6 and TGF-β, the concentration of each cytokine was measured in culture supernatants. IL-1β and IL-17 showed synergistic effects on the concentrations of IL-6 and TGF-β in both murine and human dermal fibroblasts, although the effect of each cytokine alone was marginal (Figures 1C,D).

More Severe Fibrosis of Skin and Lung in IL-1Ra-KO Mice Depends on IL-17 Signaling
IL-1Ra is an endogenous inhibitor of IL-1 activity that competes with IL-1 (IL-1α and IL-1β) for binding to the IL-1 receptor. IL-1Ra-KO mice on a BALB/c background were developed by Iwakura et al. for use as an animal model of spontaneous arthritis (26). Iwakura and colleagues identified that IL-17 production is markedly induced in IL-1Ra-KO mice and that the inflammatory arthritis in that animal model requires IL-17 and T cells (27). To investigate the pathophysiological role of IL-17 during the development of dermal and pulmonary fibrosis, the subcutaneous BLM-induced SSc model was developed in WT BALB/c, IL-1Ra-KO mice, and DKO mice (IL-1Ra–IL-17-DKO). After 4 weeks of BLM injection, skin and lung tissues were extracted and analyzed. Histological analyses of skin and lung samples stained with H&E or MT (for collagen identification) showed that BLM injection in WT mice increased dermal thickness, caused greater ECM deposition in the dermis, and induced greater fibrosis of adipose tissue in the subcutaneous layer relative to the results following injection of PBS (Figure 2A). And, BLM-induced skin and lung fibrosis was significantly greater in IL-1Ra-KO mice than in WT BALB/c mice (Figures 2A,B). Intriguingly, IL-1Ra–IL-17-DKO mice showed significantly attenuated fibrosis and less collagen deposition in skin and lung tissues than did IL-1Ra-KO mice (Figures 2A,B). Deposition of collagen in skin and lung tissues, quantified by measuring the level of hydroxyproline, also significantly increased in IL-1Ra-KO mice compared to WT BALB/c mice (Figures 2A,B). This increase in hydroxyproline content shown in IL-1Ra-KO mice was significantly reduced in IL-1Ra–IL-17-DKO mice (Figures 2A,B). Next, to examine the changes in inflammatory cytokines, quantitative real-time PCR was used to analyze skin samples from each group of mice. mRNA expression of IL-1β, IL-6, IL-17, and TNF-α was much higher in IL-1Ra-KO mice than in WT mice (Figure 2C). And, the mRNA levels of all of these genes were significantly lower in IL-1Ra–IL-17-DKO mice than in IL-1Ra-KO mice (Figure 2C). By contrast, TGF-β expression in affected skin did not differ between the WT mice and IL-1Ra-KO mice, although there was marginal difference between IL-1Ra-KO mice and IL-1Ra–IL-17-DKO mice, which suggests that TGF-β signaling is not associated with IL-1β- and IL-17-induced augmented fibrosis (Figure 2C).

Furthermore, to identify the effect of IL-17 on the altered fibrosis severities shown in IL-1Ra-KO mice and IL-1Ra–IL-17-DKO mice, dermal fibroblasts isolated from IL-1Ra-KO mice were cocultured with in vitro differentiated Th17 cells that were generated using splenic CD4+ T cells from IL-1Ra-KO mice. After 3 days of coculture, T cells were washed out and dermal
fibroblasts were then harvested and analyzed for fibrosis-associated gene expressions. The results showed that MMP1, MMP9, Col1A1, and TGFβ mRNA expressions were significantly increased in the dermal fibroblasts cultured with Th17 cells compared to those in single cultured system (Figure 2D). And, this increase was attenuated or abolished by anti-IL-17 antibody with IL-17 blocking property (Figure 2D). Taken together, these findings suggest that the increased dermal thickness and collagen deposition shown in BLM-treated IL-1Ra-KO mice is largely dependent on the activity of IL-17 located in the downstream signal of IL-1β.

The Expression of Inflammatory and Fibrotic Cytokines in Affected Skin

Immunohistochemical staining was performed on skin samples from the four animal groups (PBS-injected negative control, BLM-induced fibrosis in WT BALB/c mice, BLM-induced fibrosis in IL-1Ra-KO mice, and BLM-induced fibrosis in IL-1Ra–IL-17-DKO mice). The numbers of IL-1β-, IL-6-, IL-17-, and TNF-α-expressing cells were significantly greater in BLM-injected IL-1Ra-KO mice than in WT BALB/c mice. By contrast, the number of TGF-β-expressing cells did not differ between these two groups (Figures 3A,B). These results suggest that augmented tissue fibrosis and inflammation caused by excessive IL-1β activity are associated with IL-6, IL-17, and TNF-α, but not with TGF-β. Further, to study whether the attenuated fibrosis in IL-1Ra–IL-17-DKO mice was associated with inflammatory and fibrotic mediators, immunohistochemical staining results of IL-1Ra/IL-17 DKO mice were compared with those of IL-1Ra-KO. The expression levels of IL-1β, IL-6, IL-17, TNF-α, and TGF-β were all significantly lower in IL-1Ra–IL-17-DKO mice than in IL-1Ra-KO mice (Figures 3A,B).
Inhibition of Inflammatory and Fibrotic Molecules and Suppression of the Infiltration of T and B Cells and Macrophages by Blocking IL-17 Activity in the Mouse Model of SSC

To identify the altered populations of immune cells, the populations of T cells, B cells, and macrophages infiltrating into dermal tissues in each group of mice were evaluated by immunohistochemical staining against CD3 (T cells), CD22 (B cells), and F4/80 (macrophages). Fewer cells of each type were detected in IL-1Ra–IL-17-DKO mice than in IL-1Ra-KO mice (Figures 4A, B).

Antifibrotic and Anti-Inflammatory Properties of IL-1Ra in BLM-Induced SSC Model

We investigated the therapeutic effect of an IL-1Ra (anakinra) in the BLM-induced fibrosis model in mice with a C57BL/6 background. After 4 weeks of BLM injection, skin and lung tissues were extracted and analyzed. Both BLM-injected C57BL/c mice showed evident fibrosis of the skin and lungs (Figure 5A). To ascertain whether anakinra could attenuate the fibrosis in the skin and lung in BLM-induced fibrosis mice, 100 mg/kg anakinra was injected intraperitoneally three times per week for 2 weeks (from day 15...
to day 28) after the start of BLM administration. Anakinra treatment in this BLM-induced fibrosis model caused marked reduction in collagen deposition and fibrosis of skin and lung tissues (Figures 5A,B). Next, the expression of inflammatory cytokines was examined in the skin tissues of each group. Activated dermal myofibroblasts are key effector cells in SSc that synthesize the excessive production of collagen, which causes fibrosis in affected organs, especially in the skin and lung (28, 29). The expression levels of IL-1β, IL-6, IL-17, TNF-α, TGF-β, and α-SMA (as a myofibroblast marker) were all decreased by anakinra treatment, which suggested anti-inflammatory and antifibrotic effects of the IL-1Ra in this BLM-induced fibrosis model (Figure 5C).

**Antifibrotic and Anti-Inflammatory Properties of IL-1Ra in Sclerotic Chronic GVHD Model**

Systemic sclerosis is an immune disorder characterized by fibrosis and autoimmunity. However, the BLM-induced fibrosis model reflects only the fibrosis and inflammation of SSc and cannot fully represent the role of autoimmunity, which is a major treatment target of SSc. cGVHD provides another model to study SSc and produces progressive fibrosis in the skin, liver, gastrointestinal tract, and lung. The cGVHD model reflects all of the major pathologies of SSc, including inflammation, fibrosis, and autoimmunity. We used the cGVHD model to confirm the pathological role of IL-1β–IL-17 signaling in the autoimmuneological aspects of SSc. Irradiated recipient C57BL/6 mice received donor BM cells and splenocytes (1 × 10⁷ cells) from one of three different kinds of donor mice with a BALB/c background: WT, IL-1Ra-KO, or IL-1Ra–IL-17-DKO mice (Figure 6A). Weight loss was greater in recipient mice that received BM cells and splenocytes from IL-1Ra-KO mice but was less in mice that received cells from IL-1Ra–IL-17-DKO mice (Figure 6A). Skin and lung are major target organs in cGVHD. These organs were isolated from the three groups of cGVHD mice at 60 days after BMT and then analyzed histologically. Similar to the patterns of weight changes, more severe inflammation was observed in the skin, and lung of recipient mice that received BM cells and splenocytes from IL-1Ra-KO mice but was less in mice that received cells from IL-1Ra–IL-17-DKO mice (Figure 6A). The accelerated tissue inflammation and fibrosis were reversed by blocking IL-17 (in IL-1Ra–IL-17-DKO mice). Taken together, these findings in two different animal models suggest that excessive IL-1β activity...
exacerbates target tissue fibrosis and inflammation by augmenting downstream IL-17 activity.

**DISCUSSION**

In the present study, we investigated the pathophysiological roles of IL-1 and its downstream cytokine IL-17 in fibrosis and inflammation of target tissues in SSc. We found that IL-1 and IL-17 activity was increased in skin and lung tissues of murine models of SSc. We present evidence that IL-1-mediated skin and lung fibrosis depends on IL-17 activity and is associated with IL-6 and TNF-α activity, but not with TGF-β. Our *in vitro* study showed that IL-1β and IL-17 have synergistic stimulatory effects on IL-6 and MMP-9 production in murine and human skin fibroblasts. This pathophysiological role of the IL-1–IL-17 axis was confirmed in two different murine models of SSc in our present study.

Here, we found that IL-1 activity may contribute to fibrosis by inducing IL-6 and TGF-β expression in skin fibroblast and resulted in increased fibrosis in BLM-induced SSc model. We identified that exacerbated fibrosis and inflammation by IL-1 activity shown *in vivo* is largely dependent on IL-17. IL-1β, one of proinflammatory cytokine, has been unrevealed to promote collagen synthesis and aggregate fibrosis, suggesting its profibrotic property (30, 31). Previous studies have demonstrated the abnormally high activities of IL-1 as well as IL-1 receptor in SSc patients (32, 33), indicating the pathophysiological roles of IL-1 signal transduction in SSc. Recently, Wilson et al. reported that intratracheal administration of IL-1β induces pulmonary fibrosis similar to BLM-induced fibrosis model, which is dependent on IL-17 activity (34). Their study is consistent with our findings showing that BLM-induced tissue fibrosis was exacerbated by systemically increased IL-1 activity through IL-1Ra depletion. Here, we demonstrated that IL-1 and IL-17, located in the downstream signal of IL-1, are important therapeutic targets for fibrosis inhibition of SSc. Furthermore, we identified that blocking the IL-1 receptor *in vivo* by anakinra administration significantly attenuated BLM-induced tissue fibrosis.

In our results, mRNA expression of type 1 collagen was increased when dermal fibroblasts isolated from IL-1Ra-KO mice were cocultured with murine Th17 cells (as shown in Figure 2D). Despite of recent recognition of the pathophysiological roles of IL-17 or Th17 cells in SSc, there have been conflicting results observed between the mice and human data. As with our findings, murine skin fibroblasts increased collagen synthesis by IL-17 treatment in a dose-dependent manner (15). Also *in vivo*, hypodermal thickness was reduced by IL-17 deficiency in a murine model of SSc (15). Most of the mice results have shown the pro-fibrotic effects of IL-17 or Th17 in SSc, both *in vitro* and *in vivo* experiments (34–37). On the other hand, in human, existing evidences have demonstrated the conflicting conclusion. In patients with SSc, the number of IL-17-expressing cells and mRNA expressions of IL-17 are increased in SSc skin than in healthy control skin (7, 11). However, treatment with IL-17 or Th17 cell supernatants in human skin fibroblast did not increase the production of type 1 collagen and connective tissue growth factor (7, 38, 39), whereas IL-17 enhanced fibroblast proliferation (7).
Thus, further studies are needed to clarify the effect of Th17 or IL-17 on human fibroblasts, regarding the progressive fibrosis of SSc target organs, such as skin and lung.

Few treatment options can effectively suppress or reverse progressive tissue fibrosis in SSc patients. These options include methotrexate, cyclophosphamide, or autologous hematopoietic stem cell transplantation (40–42). However, the therapeutic efficacy of these strategies is limited because of the restricted duration of the time when the condition can be improved, the marginal effectiveness of these treatments, and the very narrow selection of candidate patients (41–43). In addition, the potential risks seem to outweigh the effectiveness of these treatments. Significant side effects include: liver toxicity, pancytopenia, teratogenicity, and lung toxicity, which are associated with methotrexate or cyclophosphamide treatment; and procedure-related mortality, associated with the hematopoietic stem cell transplantation (44). Despite the emerging concept of the use of molecular targets, such as endothelin-1, for the treatment of fibrosis in SSc, the clinical efficacy and safety profile of antifibrotic treatments including tyrosine kinase inhibitors such as imatinib await confirmation (45–48).

In our present study, we identified the pathophysiological role of IL-1 and its downstream IL-17 activity in SSc-associated inflammation and fibrosis using two different murine models of the disease. We found that increased IL-1 activity aggravated fibrosis in the skin and lung tissues of SSc mice and that fibrosis exacerbated by this increased IL-1 activity could be reversed by blocking IL-17. Our findings implicate IL-1β and its downstream
IL-17 signaling in the tissue fibrosis, inflammation, and autoimmunity involved in SSc. Our results imply that IL-1–IL-17 signaling may be a novel therapeutic target for attenuating or reversing ongoing inflammation and fibrosis in SSc patients.

ETHICS STATEMENT

Human dermal fibroblasts were isolated from foreskin tissue obtained from Bucheon St. Mary’s Hospital. The isolation of dermal fibroblasts has been described previously (18). Human experiments were approved by the Institutional Review Board (IRB) of human subjects at Bucheon St. Mary’s Hospital (approval number: HC18TES10013), The Catholic University of Korea, and conducted accordance with IRB guidelines and regulations.

All patients were informed and gave their written consent and this study was performed in accordance with the Helsinki II Declaration.

AUTHOR CONTRIBUTIONS

All the authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. M-LC and S-HP had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. M-JP, S-JM, S-HP, and M-LC contributed to study conception, study design, data acquisition, analysis, and interpretation and drafted the manuscript. E-JL, K-AJ, E-KK, and D-SK contributed...
to data acquisition, analysis, and interpretation. J-HL, S-KK, and J-KM contributed to analysis and interpretation of data.

FUNDING

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C1062), by the National Research Foundation of Korea (NRF) grant funded by the Korea government(MSIP) (NRF-2017R1A2B3007688), by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT) (No. NRF-2018R1A2B6007291) and by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIP) (No. NRF-2017R1C1B2007439).

REFERENCES

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med (2009) 360:1989–2003. doi:10.1056/NEJMra0806188
2. Guiducci S, Distler O, Distler JH, Matucci-Cerinic M. Mechanisms of vascular damage in SSc: implications for vascular treatment strategies. Rheumatology (Oxford) (2008) 47(Suppl 5):v18–20. doi:10.1093/rheumatology/ken267
3. Parel Y, Aurand-Lions M, Scheja A, Dayer JM, Roosnek E, Chizzolini C. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum (2007) 56:3459–67. doi:10.1002/art.22927
4. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol (1992) 166:255–63. doi:10.1002/path.171660307
5. Harrison NK, Myers AR, Corbin B, Soosay G, Dewar A, Black CM, et al. Structural features of intestinal lung disease in systemic sclerosis. Am Rev Respir Dis (1991) 144:706–13. doi:10.1164/arrjcp.144.3 Pt _1.706
6. Singh RP, Hasan S, Sharma S, Nagra S, Yamaguchi DT, Wong DT, et al. Th17 cells in inflammation and autoimmunity. Autoimmun Rev (2014) 13:1174–81. doi:10.1016/j.autrev.2014.08.019
7. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. J Pathol (2014) 233:169–77. doi:10.1002/path.3180
8. Yonenaga S, Takeda M, Hara T, Muroi E, et al. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Rheumatol (2012) 39:1312–20. doi:10.3899/jrheum.120103
9. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of interleukin-10 results in pulmonary fibrosis and recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum (2007) 56:334–44. doi:10.1002/art.22328
10. Xing X, Yang J, Wang X, Wei Y, Zhu L, Gao D, et al. IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. Arthritis Res Ther (2012) 14:R124. doi:10.1186/ar3971
11. Truchetet ME, Brembilla NC, Montanari E, Lonati P, Raschi E, Zeni S, et al. Th17 cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int (2016) 36:1989–2003. doi:10.1002/art.22927
12. Lei L, Zhao C, Qin F, He ZY, Wang X, Zhong XN. Th17 cells and IL-17 promote the development of systemic sclerosis. J Rheumatol (2014) 41:1174–81. doi:10.1003/1523-1747.101208-1
13. Fossiez F, Dyooso O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med (1996) 183:2593–603. doi:10.1084/jem.183.6.2593
14. Xiong X, Yang J, Yang X, Wei Y, Zhu L, Gao D, et al. IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. PLoS One (2013) 8:e50302. doi:10.1371/journal.pone.0050302
15. Truchetet ME, Brembilla NC, Montanari E, Lonati P, Raschi E, Zeni S, et al. Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. Arthritis Rheum (2013) 65:1347–56. doi:10.1002/art.37860
16. Lei L, Zhao C, Qin F, He ZY, Wang X, Zhong XN. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis. Clin Exp Rheumatol (2016) 34(Suppl 100):14–22.
17. Chizzolini C, Dufour AM, Brembilla NC. Is there a role for IL-17 in the pathogenesis of systemic sclerosis? Immunol Lett (2018) 195:61–7. doi:10.1016/j.imlet.2017.09.007
18. Yang X, Yang J, Xing X, Wan L, Li M. Increased frequency of CD45R0+ T cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther (2014) 16:R4. doi:10.1186/ar4430
19. Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Hsu DL, Ikawara Y, et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum (2012) 64:3726–35. doi:10.1002/art.31463
20. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, et al. CD19 regulates skin and lung fibrosis via toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol (2008) 172:1650–63. doi:10.2353/ajpath.2008.071049
21. Rogers KM, Black DH, Eberle R. Primary mouse dermal fibroblast cell cultures as an in vitro model system for the differential pathogenicity of cross-species herpervirus papio 2 infections. Arch Virol (2007) 152:543–52. doi:10.1007/s00705-006-0865-1
22. Sato S, Sato T, Fujimoto M, Iba H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 increase in patients with systemic sclerosis. J Rheumatol (1998) 25:308–13.
23. Kurosawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al. Th17 interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum (2000) 43:2455–63. doi:10.1002/1529-0131(200011)43:11<2455:aaid-ar2>3.0.co;2-k
24. Rodriguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J, Fajardo-Hernosillo LD, Martinez-Reyes C, Diaz-Zamudio M, et al. Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int (2012) 32:2653–60. doi:10.1002/art.30296-011-2056-y
25. Kurosawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum (2000) 43:2455–63. doi:10.1002/1529-0131(200011)43:11<2455:aaid-ar2>3.0.co;2-k
26. Kurosawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum (2000) 43:2455–63. doi:10.1002/1529-0131(200011)43:11<2455:aaid-ar2>3.0.co;2-k
27. Park et al. Pathologic Role of IL-1 and IL-17 in SSc

Frontiers in Immunology | www.frontiersin.org 11 July 2018 | Volume 9 | Article 1611
34. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med (2010) 207:535–52. doi:10.1084/jem.20092121
35. Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma YG, et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol (2011) 187:3003–14. doi:10.4049/jimmunol.1004081
36. Gasse P, Riteau N, Vacher R, Michel ML, Fautrel A, di Padova F, et al. IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS One (2011) 6:e23185. doi:10.1371/journal.pone.0023185
37. Simonian PL, Roark CL, Wehrmann F, Lanham AK, Diaz del Valle F, Born WK, et al. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol (2009) 182:657–65. doi:10.4049/jimmunol.182.1.657
38. Nakashima T, Innin M, Yamane K, Honda N, Kajihara I, Makino T, et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol (2012) 188:3573–83. doi:10.4049/jimmunol.1100591
39. Brembilla NC, Montanari E, Truchetet ME, Raschi E, Meroni P, Chizzolini C. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther (2013) 15:R151. doi:10.1186/ar4334
40. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis (2017) 76:1327–39. doi:10.1136/annrheumdis-2016-209909
41. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Forst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med (2006) 354:2655–66. doi:10.1056/NEJMoa055120
42. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA (2014) 311:2490–8. doi:10.1001/jama.2014.6368
43. Pope JE, Bellamy N, Seibold JR, Baron M, Elinman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum (2001) 44:1351–8. doi:10.1002/1529-0131(200106)44:6<1351::AID-art227>3.0.co;2-i
44. Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf (2005) 4:723–30. doi:10.1517/14740338.4.4.723
45. Denton CP, Merkel PA, Forst DE, Khanna D, Emery P, Hsu VM, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum (2007) 56:323–33. doi:10.1002/art.22289
46. Pope J, McBain D, Petrilich L, Watson S, Vanderhoek L, de Leon F, et al. Imitinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum (2011) 63:3547–51. doi:10.1002/art.30549
47. Bournia VK, Evangelou K, Sfikakis PP. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib. Semin Arthritis Rheum (2013) 42:377–90. doi:10.1016/j.semarthrit.2012.06.001
48. Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA (2016) 315:1975–88. doi:10.1001/jama.2016.5258

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Park, Moon, Lee, Jung, Kim, Kim, Lee, Kwok, Min, Park and Cho. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.